Companies: 10,795·Total market cap: $144.5T
Athira Pharma, Inc.

Athira Pharma, Inc.

ATHANASDAQHealthcare
$6.75
$-0.44(-6.12%)
Market Cap$26621237
P/E Ratio
52W High$8.36
52W Low$2.1955
Overview

Athira Pharma, Inc. (ATHA) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001620463 · ATHA · NASDAQ · as of Jun 9, 2026

Filing snapshot

439
Total Filings
SCHEDULE 13G
Latest Form
2026-05-15
Most Recent
2020
Filing Since

Source: SEC EDGAR (data.sec.gov) · CIK 0001620463 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-03-31
Fiscal Year End
Mar 31, 2026
Accession No.
0001193125-26-134565
Primary Document
lona-20251231.htm
Source: data.sec.gov · CIK 0001620463 · Accession 0001193125-26-134565

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-07
8-KCurrent Report
8-K
2026-05-07Material Event
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

SEC Filing History

Hide Form 4 / 144
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-05-15
View
ARSARS
ARS
2026-05-11
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-05-11
View
DEF 14AProxy Statement
DEF 14A
2026-05-11
View
3Initial Statement of Beneficial Ownership
Initial Statement of Beneficial Ownership
2026-05-07
View
3Initial Statement of Beneficial Ownership
Initial Statement of Beneficial Ownership
2026-05-07
View
3Initial Statement of Beneficial Ownership
Initial Statement of Beneficial Ownership
2026-05-07
View
SCHEDULE 13D/ASCHEDULE 13D/A
SCHEDULE 13D/A
2026-05-07
View
10-QQuarterly Report
10-Q
2026-05-07
View
8-KCurrent Report
8-K
2026-05-07
View
424B3424B3
424B3
2026-04-02
View
424B3424B3
424B3
2026-04-02
View
EFFECTEFFECT
EFFECT
2026-04-01
View
EFFECTEFFECT
EFFECT
2026-04-01
View
S-8Employee Stock Plan Registration
S-8
2026-04-01
View
Showing 1–15 of 257 filingsForm 4 / 144 hidden· 439 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001620463  |  Exchange: NASDAQ · Healthcare

Athira Pharma, Inc. (NASDAQ: ATHA) has submitted 439 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2020. As a Healthcare sector company with CIK 0001620463, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Athira Pharma, Inc.'s most comprehensive regulatory disclosure. The most recent Athira Pharma, Inc. 10-K was filed on 2026-03-31 for fiscal year ending 2026. Historical ATHA 10-K annual reports are available from 2014 through 2026.

Investors researching Athira Pharma, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-09

Frequently Asked Questions

ATHA SEC Filings · 8 questions

Athira Pharma, Inc. (ATHA) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 439 filings and access original documents at no cost. Athira Pharma, Inc.'s CIK is 0001620463.

ATHA SEC filingsAthira Pharma, Inc. SEC documentsfind ATHA 10-K